Integral Diagnostics Limited

ASX IDX.AX

Integral Diagnostics Limited EBITDA Margin for the year ending June 30, 2024: 2.63%

Integral Diagnostics Limited EBITDA Margin is 2.63% for the year ending June 30, 2024, a -87.54% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Integral Diagnostics Limited EBITDA Margin for the year ending June 30, 2023 was 21.07%, a 8.15% change year over year.
Integral Diagnostics Limited EBITDA Margin for the year ending June 30, 2022 was 19.49%, a -23.58% change year over year.
Integral Diagnostics Limited EBITDA Margin for the year ending June 30, 2021 was 25.50%, a 0.55% change year over year.
Integral Diagnostics Limited EBITDA Margin for the year ending June 30, 2020 was 25.36%, a 17.10% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

ASX: IDX.AX

Integral Diagnostics Limited

CEO	Dr. Ian Kadish M.B.A., MBBCh
IPO Date	Oct. 20, 2015
Location	Australia
Headquarters	45 William Street
Employees	1,977
Sector	Healthcare
Industries Telehealth 3D Printing Biotechnology Defense & Military Dental Care Health Insurance & Plans Hospitals & Clinics Medical Instruments

Description

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years